SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Diabetes Care: Global Investing Opportunities
NVO
|
|
|
+0.08%
in
7 days
<> The <font> American Diabetes Association estimates </font> that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billion in costs from diagnosed cases of diabetes in the U.S. (2007). On a global scale, the <font> International Diabetes Federation (IDF) estimates </font> 285 million diabetics worldwide in 2010. I have outlined some investing opportunities in this article, with a focus on emerging small / micro-c...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
NVO
|
|
|
+31.98%
in
235 days
(closed on 11/22/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Upcoming FDA Advisory Panel Meetings
NVO
|
|
|
+16.10%
in
23 days
(closed on 04/01/09)
A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials. http://www.biomedreports.com/fda-calendar.html <> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
|
Updated Clinical Trial and FDA Decision Calendars
NVO
|
|
|
-3.53%
in
3 days
(closed on 03/09/09)
<!-- Post Teaser Text --> <> Below is a summary of updates to the BioMedReports.com database of 233 entries included in the FDA and Clinical Trial Calendars . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. <> The entries are updated on a daily basis as new information becomes available with a total of 101 entries through ...
|
Scandinavian Select Nordic Region Index
NVO
|
|
|
-18.65%
in
57 days
(closed on 03/06/09)
<> 
<>
The accompanying table [click to enlarge] includes statistics for all 82 companies in the ETF Innovators [ETFI] Scandinavian Select Nordic Region Index, which was last updated in mid-December.
This index tracks the performance of companies in the Nordic Region with market caps over $1B U.S. Dollars and would include the Top 35 Rated Companies as a new idea for a semi-active ETF with quarterly rebalancing as compared to the pending passive ETF for the Nordic Region filed by Global X whic...
|
From the Blogosphere
Spotlight on Biotech: 10 Promising Companies
The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen (AMGN), Biogen Idec (BIIB), Genetic (GENE), Genzyme (GENZ), Life Technologies (LIFE) and Monsanto (MON). Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. <>Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this ind...
|
Global pharma favorites
NVO
Global pharma favorites
|
|
|
 In a review of the pharmaceutical sector, Chuck Carlson selects his favorite International stocks which also offer direct-purchase plans for U.S. investors.
Here's a look at two of these stocks -- United Kingdom-based AstraZeneca (NYSE: AZN) and Denmark-based Novo Nordisk (NYSE: NVO) -- from his The DRIP Investor, a newsletter focused on long-term, high quality investments. "AstraZeneca is a leading pharmaceutical ?rm. The company boasts a portfolio that includes 11 products that generate more than $1 billion each in annual sales. <>"Top drugs include Crestor (cholesterol) and Symbicort (asth...
|
Analyst upgrades, downgrades and initiations: MF, IBM, CSCO, RTP, BAC, C, ANF ...
Filed under: Analyst reports, Analyst upgrades and downgrades, Cisco Systems (CSCO), Viacom (VIA), International Business Machines (IBM), Citigroup Inc. (C), JPMorgan Chase (JPM), Bank of America (BAC), Abercrombie and Fitch (ANF), Analyst initiations, Rio Tinto plc ADS (RTP)  Analyst upgrades:
<> Keefe Bruyette upgraded MF Global (NYSE: MF) to Outperform from Market Perform as it believes the company's liquidity position has improved and that it is well positioned to take market share. The firm raised its target on shares to $9.
<>UBS upgraded Wynn Resorts (NASDAQ: WYNN) to Buy from Neutra...
|
Notable Analyst Rating Changes 4/6: WYNN, JOYG, BUCY, TWC, NVO Upgraded; CSCO, ICE, ABT, VIA, BHP, RTP Downgraded
UPGRADES:UBS upgrades Wynn Resorts (Nasdaq: WYNN) from Neutral to Buy with a $33 price target.JP Morgan upgrades Joy Global (Nasdaq: JOYG) and Bucyrus (Nasdaq: BUCY) from Underweight to Neutral, citing easing credit markets and stabilizing mining project cancellations.Collins Stewart upgrades Time Warner Cable (NYSE: TWC) to Buy. Price target $34. Click here for more color on the upgrade.SocGen upgrades Novo Nordisk (NYSE: NVO) from Sell to Hold. For daily real-time Upgrades go to http://www.streetinsider.com/UpgradesDOWNGRADES:Goldman Sachs downgrades Cisco (Nasdaq: CSCO) from Buy to Neut...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About NovoNordisk A/S
- Answers.com
